

Bone and Soft Tissue Pathology Monthly Series - 5/26/2025
5/26/2025 12:00:00 PM - 5/26/2025 1:00:00 PM

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact MDAnderson-CPE@mdanderson.org

Target Audience:

Professions: Physician (MD or DO), Student or Trainee

Learning Objectives:

- 1 Demonstrate the importance of accurate diagnosis for bone and soft tissue tumors.
- 2 Illustrate the challenges in bone soft tissue pathology and how ancillary testing can be useful to overcome them and improve patient outcomes.

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology MOC Credit:

This activity has been registered to offer credit in the American Board of Pathology's Continuing Certification program. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Lifelong Learning credits. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit.

Commercial Support:

No commercial support has been received for this activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty,

planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Wei-Lien Wang, MD	Activity Director, Faculty	Nothing to disclose - 01/03/2025
Alexander Lazar, MD, FCAP	Activity Co-Director	Advisor-AbbVie Inc. Advisor-Bayer HealthCare Pharmaceuticals, Inc. Advisor-Bristol-Myers Squibb Company Advisor-GlaxoSmithKline Advisor-Merck Sharp & Dohme Corp. (any division) Advisor-Novartis Pharmaceuticals Corporation Advisor-Genentech, Inc. Advisor-Pfizer Inc. Advisor-Regeneron Pharmaceuticals, Inc. - 01/03/2025